Hereditary tyrosinemia type 1 from a single center in Egypt: Clinical study of 22 cases

World Journal of Pediatrics

Volumn 7, Issue 3, 2011, Pages 224-231

  El Karaksy, Hanaa ^a   Fahmy, Mona ^b   El Raziky, Mona ^a   El Koofy, Nehal ^a   El Sayed, Rokaya ^a   Rashed, Mohamed S ^c,d   El Kiki, Hasan ^a   El Hennawy, Ahmad ^a   Mohsen, Nabil ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b RESEARCH INSTITUTE OF OPHTHALMOLOGY   (Egypt)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d Pharmagene Laboratory   (Egypt)

Author keywords

2 (2 nitro 4 trifluoro methylbenzoyl) 1,3 cyclohexanedione (NTBC); Children; Egypt; Hereditary tyrosinemia type 1; Liver transplantation

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; NITISINONE; PHOSPHATE; SUCCINYLACETONE;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HEPATOMEGALY; HEREDITARY TYROSINEMIA TYPE 1; HUMAN; INFANT; LIVER INJURY; LIVER TRANSPLANTATION; LIVING DONOR; MALE; MORTALITY; PHOSPHATE BLOOD LEVEL; PRESCHOOL CHILD; RICKETS; TREATMENT RESPONSE; TYROSINEMIA;

CHILD, PRESCHOOL; CYCLOHEXANONES; EGYPT; ENZYME INHIBITORS; FEMALE; HUMANS; INFANT; LIVER TRANSPLANTATION; MALE; NITROBENZOATES; TYROSINEMIAS;

EID: 80054996308     PISSN: 17088569     EISSN: 18670687     Source Type: Journal    
DOI: 10.1007/s12519-011-0287-3     Document Type: Article

References (33)

1. Labelle Y, Phaneuf D, Leclerc B, Tanguay RM. Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity. Hum Mol Genet 1993;2:941-946. (Pubitemid 23216625)
2. Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci USA 1977;74:4641-4645. (Pubitemid 8225182)
3. Kvittingen E. Hereditary tyrosinemia type I-an overview. Scand J Clin Lab Invest Suppl 1986;184:27-34. (Pubitemid 17008106)
4. Russo P, O'Regan S. Visceral pathology of hereditary tyrosinemia type I. Am J Hum Genet 1990;47:317-324.
5. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992;340:813-817.
6. Holme E, Lindstedt S. Nontransplant treatment of tyrosinemia. Clin Liver Dis 2000;4:805-814.
7. Al-Dirbashi OY, Rashed MS, Brink HJ, Jakobs C, Filimban N, Al-Ahaidib LY, et al. Determination of succinylacetone in dried blood spots and liquid urine as a dansylhydrazone by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006;831:274-280. (Pubitemid 43155805)
8. El-Karaksy H, Rashed M, El-Sayed R, El-Raziky M, El-Koofy N, El-Hawary M, et al. NTBC Therapy for tyrosinemia type 1: how much is enough? Eur J Pediatr 2010;169:689-693.
9. Hafez M, El-Tahan H, Awadalla M, El-Khayat H, Abdel-Gafar A, Ghoneim M. Consanguineous matings in the Egyptian population. J Med Genet 1983;20:58-60. (Pubitemid 13189478)
10. Mokhtar MM, Abdel-Fattah MM. Consanguinity and advanced maternal age as risk factors for reproductive losses in Alexandria, Egypt. Eur J Epidemiol 2001;17:559-565. (Pubitemid 34252684)
11. De Braekeleer M, Larochelle J. Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St- Jean. Am J Hum Genet 1990;47:302-307.
12. Croffi e JM, Gupta SK, Chong SK, Fitzgerald JF. Tyrosinemia type 1 should be suspected in infants with severe coagulopathy even in the absence of other signs of liver failure. Pediatrics 1999;103:675-678. (Pubitemid 29274521)
13. Mitchell GA, Russo P, Dubois J, Alvarez F. Tyrosinemia. In: Suchy FJ, eds. Liver Disease in Children, 2nd ed. St. Louis: Mosby-Year Book, 2001: 667-686.
14. Kvittingen EA, Talseth T, Halvorsen S, Jakobs C, Hovig T, Flatmark A. Renal failure in adult patients with hereditary tyrosinaemia type I. J Inherit Metab Dis 1991;14:53-62.
15. Mitchell G, Larochelle J, Lambert M, Michaud J, Grenier A, Ogier H, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med 1990;322:432-437. (Pubitemid 20059512)
16. Jorquera R, Tanguay RM. Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis. FASEB J 1999;13:2284-2298.
17. Jorquera R, Tanguay RM. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum Mol Genet 2001;10:1741-1752. (Pubitemid 32899091)
18. Luijerink MC, Jacobs SM, van Beurden EA, Koornneef LP, Klomp LW, Berger R, et al. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4- trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC). J Hepatol 2003;39:901-909. (Pubitemid 37523760)
19. McKiernan PJ. Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 2006;66:743-750. (Pubitemid 43765222)
20. Crone J, Moslinger D, Bodamer OA, Schima W, Huber WD, Holme E, et al. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I. Acta Paediatr 2003;92:625-628. (Pubitemid 37088712)
21. Ashorn M, Pitkanen S, Salo MK, Heikinheimo M. Current strategies for the treatment of hereditary tyrosinemia type I. Pediatr Drugs 2006;8:47-54.
22. van Spronsen FJ, Bijleveld CM, van Maldegem BT, Wijburg FA. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr 2005;40:90-93. (Pubitemid 40180065)
23. Hostetter MK, Levy HL, Winter HS, Knight GJ, Haddow JE. Evidence for liver disease preceding amino acid abnormalities in hereditary tyrosinemia. N Engl J Med 1983;308:1265-1267. (Pubitemid 13092696)
24. Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, et al. NTBC treatment in tyrosinemia type I: long-term outcome in French patients. J Inherit Metab Dis 2008;31:81-87.
25. Liou J, Lee JKT, Borrello JA, Brown JJ. Differentiation of hepatomas from non-hepatomatous masses: use of MnDPDP enhanced MR images. Magn Res Imaging 1994;12:71-79.
26. Dubois J, Garel L, Patriquin H, Paradis K, Forget S, Filiatrault D, et al. Imaging features of type 1 hereditary tyrosinemia: a review of 30 patients. Pediatr Radiol 1996;26:845-851. (Pubitemid 26402119)
27. Forget S, Patriquin HB, Dubois J, Lafortune M, Merouani A, Paradis K, et al. The kidney in children with tyrosinaemia: sonographic, CT and biochemical findings. Pediatr Radiol 1999;29:104-108. (Pubitemid 29134449)
28. Santra S, Preece MA, Hulton SA, McKiernan PJ. Renal tubular function in children with tyrosinaemia type I treated with nitisinone. J Inherit Metab Dis 2008;31:399-402.
29. Grompe M, Overturf K, Al-Dhalimy M, Finegold M. Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report. J Inher Metab Dis 1998;21:518-531. (Pubitemid 28391504)
30. Al-Dhalimy M, Overturf K, Finegold M, Grompe M. Longterm therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Mol Genet Metab 2002;75:38-45. (Pubitemid 34971533)
31. Holme E, Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifl uoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 1998;21:507-517. (Pubitemid 28391503)
32. Hanauske-Abel HM, Popowicz A, Remotti H, Newfield RS, Levy J. Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism. J Pediatr Gastroenterol Nutr 2002;35:73-78. (Pubitemid 34778760)
33. Mohan N, McKiernan P, Preece MA, Green A, Buckels J, Mayer AD, et al. Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 1999;158 Suppl. 2:S49-54.